Related Experiment Video
Updated: Sep 30, 2025
08:17
Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
Published on: June 7, 2015
15.9K
Early-Stage Non-Small Cell Lung Cancer Stereotactic Body Radiation Therapy Outcomes in a Single Institution
Nathan P Doupnik1, Khalid Hirmiz1, Abdulkadir A Hussein2
1Department of Radiation Oncology, Windsor Regional Hospital, Windsor, CAN.
Cureus
|March 11, 2022
Summary
Stereotactic body radiation therapy (SBRT) offers superior three-year local control (LC) and survival for early-stage non-small cell lung cancer (NSCLC) compared to other radiation methods. SBRT demonstrates comparable complication rates, making it an effective treatment option.
Area of Science:
- Oncology
- Radiation Oncology
- Pulmonology
Background:
- Surgical resection is the gold standard for early-stage non-small cell lung cancer (NSCLC).
- Stereotactic body radiation therapy (SBRT) is an alternative for medically inoperable patients, offering comparable local control (LC) and overall survival (OS).
- Comparative data on SBRT versus other radiation modalities for early-stage NSCLC at a single institution is limited.
Purpose of the Study:
- To determine and compare three-year LC and OS for SBRT versus alternative radiation modalities in early-stage NSCLC.
- To evaluate treatment-related toxicities across different radiation fractionation schemes.
- To identify prognostic factors influencing survival in early-stage NSCLC patients treated with radiation.
Main Methods:
- Retrospective review of 139 consecutive early-stage NSCLC patients treated with radiation between 2015-2020.
- Treatment subgroups included SBRT, hypofractionation, conventional fractionation, and palliative radiation.
- Kaplan-Meier curves and Cox proportional hazard regression analysis were used to assess LC, OS, and survival risks.
Main Results:
- Three-year LC was significantly higher with SBRT (94%) compared to hypofractionation (71%), conventional fractionation (80%), and palliative radiation (71%).
- Three-year OS was highest with SBRT (67%), followed by conventional fractionation (66%), hypofractionation (59%), and palliative radiation (44%).
- SBRT showed comparable or lower rates of radiation pneumonitis and dermatitis than other modalities, with no grade III+ toxicities observed.
Conclusions:
- SBRT provides durable three-year local control and overall survival for early-stage NSCLC, with complication rates comparable to other radiation techniques.
- SBRT is a safe and effective treatment option for early-stage NSCLC, particularly for patients ineligible for surgery.
- Age and treatment modality significantly impact survival outcomes, with SBRT demonstrating superior results compared to hypofractionation and palliative radiation.
